First ColoSTAT Clinical Test Sale
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited reports the first commercial sale of its ColoSTAT colorectal cancer test, marking the start of its clinical diagnostic operations. The company has successfully validated the entire clinical pathway from blood collection to result delivery in a routine setting. Rhythm plans to scale operations through direct physician engagement and its ColoSTAT Access Program. Updates on commercial progress and adoption rates will be provided in regular quarterly reports.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- NATA Accredits ColoSTAT Clinical Testing Service
- RHY Executes SE Asian Genetype Distribution Agreement
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- Trading Halt
- Half-Year Financial Report and Appendix 4D
Later from Rhythm Biosciences
- Response to ASX Query Letter
- FY26 Appendix 4E & Audited Financial Report
- Initial ColoSTAT Assessment in UK opens new market access
- ColoSTAT Economic Study - Australian Public Health Savings
- Quarterly Activities Report and Appendix 4C
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences